Nektar Therapeutics CEO Howard Robin's 2020 pay rises 13% to $11M
Nektar Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 30, 2021
Nektar Therapeutics reported fiscal year 2020 executive compensation information on April 30, 2021.
In 2020, five executives at Nektar Therapeutics received on average a compensation package of $5.8M, a 26% decrease compared to previous year.
Average pay of disclosed executives at Nektar Therapeutics
Howard W. Robin, Chief Executive Officer, received $11M in total, which increased by 13% compared to 2019. 44% of Robin's compensation, or $5M, was in stock awards. Robin also received $1.1M in non-equity incentive plan, $4M in option awards, $1.1M in salary, as well as $96K in other compensation.
Gil M. Labrucherie, Chief Financial Officer, received a compensation package of $5.3M, which decreased by 29% compared to previous year. 43% of the compensation package, or $2.2M, was in stock awards.
Jonathan Zalevsky, Chief Research and Development Officer, earned $4.9M in 2020, a 32% decrease compared to previous year.
John Northcott, Senior Vice President and Chief Commercial Officer, received $3.8M in 2020, which decreases by 40% compared to 2019.
Mark A. Wilson, General Counsel, earned $3.5M in 2020.
Related executives
Howard Robin
Nektar Therapeutics
Chief Executive Officer
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
John Northcott
Nektar Therapeutics
Senior Vice President and Chief Commercial Officer
Mark Wilson
Nektar Therapeutics
General Counsel
Jonathan Zalevsky
Nektar Therapeutics
Senior Vice President and Chief Research and Development Officer
You may also like
Source: SEC filing on April 30, 2021.